Top

Reactions Weekly

Published in:

01-04-2024 | Urothelial Cancer | Case report

Disitamab-vedotin

Lack of efficacy

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Wei Y, et al. A real-world study from two centers regarding the combination treatment of disitamab vedotin and immune checkpoint inhibitors for locally advanced bladder urothelial carcinoma: A novel bladder-preserving strategy. European Urology 85 (Suppl.): S318, Mar 2024. Available from: URL: https://dx.doi.org/10.1016/S0302-2838%2824%2900308-7 [abstract]

Title: Disitamab-vedotin
Lack of efficacy
Publication date: 01-04-2024
Publisher: Springer International Publishing
Keywords: Urothelial Cancer
Urothelial Cancer
Cystectomy
Checkpoint Inhibitors
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-57421-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Disitamab-vedotin

Lack of efficacy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

BBIBP-CorV

Multiple drugs

Trametinib

Testosterone

AZD-1222/BBIBP-CorV/COVID-19-vaccine-Gamaleya-National-Research-Center-of-Epidemiology-and-Microbiology

Liothyronine